INFO & CONTACTS:  +39 02 2390 1

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Indini Alice

Main Facility: Oncologia Medica 1

Drug: ALE.P02

Pathologies: Lung cancer

ClinicalTrials.gov: Read the details about clinical trials

This is a first in human study designed to to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and preliminary anti-tumor activity of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) in monotherapy in adult patients with selected in adult patients with selected squamous solid tumors.  

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe